BNP Paribas Financial Markets
ELVN icon

BNP Paribas Financial Markets’s Enliven Therapeutics ELVN Stock Holding History

BNP Paribas Financial Markets’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Buy
45,685
+36,058
+375% +$1.53M ﹤0.01% 2696
2026
Q1 		$377K Sell
9,627
-45
-0.5% -$1.25K ﹤0.01% 3738
2025
Q4 		$149K Buy
9,672
+528
+6% +$10.5K ﹤0.01% 4191
2025
Q3 		$187K Buy
9,144
+5,422
+146% +$109K ﹤0.01% 4039
2025
Q2 		$74.7K Buy
3,722
+930
+33% +$17.6K ﹤0.01% 4111
2025
Q1 		$54.9K Sell
2,792
-2,199
-44% -$47.3K ﹤0.01% 4261
2024
Q4 		$112K Buy
+4,991
New +$129K ﹤0.01% 4123

Other funds holding ELVN

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's ELVN Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Enliven Therapeutics (ELVN) stake by 375% in Q2 2026, buying an estimated $1.53M and bringing the position to 45,685 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2696.

BNP Paribas Financial Markets first reported a position in ELVN in Q4 2024 and has held it in 7 quarters since. 189 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • BNP Paribas Financial Markets held 45,685 shares of Enliven Therapeutics worth $2.32M as of Q2 2026.
  • BNP Paribas Financial Markets bought 36,058 Enliven Therapeutics shares in Q2 2026, an estimated $1.53M.
  • Enliven Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2696 holding.
  • BNP Paribas Financial Markets first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 189 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.